Linezolid-Resistant Enterococcus faecalis Isolated from a Cord Blood Transplant Recipient

Journal of Clinical Microbiology

Volumn 42, Issue 4, 2004, Pages 1843-1845

  Dibo, Imad ^a   Pillai, Satish K ^b   Gold, Howard S ^b   Baer, Maria R ^a   Wetzler, Meir ^a   Slack, James L ^a   Hazamy, Peggy A ^a   Ball, Donna ^a   Hsiao, Chiu Bin ^a   McCarthy Jr , Philip L ^a   Segall, Brahm H ^a,c  

^a UNIVERSITY AT BUFFALO   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITY AT BUFFALO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; ANTIBIOTIC AGENT; BACTERIAL DNA; CHLORAMPHENICOL; CORTICOSTEROID; DALFOPRISTIN PLUS QUINUPRISTIN; FOSCARNET; GENOMIC DNA; GENTAMICIN; IMMUNOGLOBULIN; LEVOFLOXACIN; LINEZOLID; NITROFURANTOIN; PENICILLIN DERIVATIVE; STREPTOMYCIN; VANCOMYCIN; VORICONAZOLE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ALPHA HEMOLYTIC STREPTOCOCCUS; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; ASPERGILLOSIS; BACTEREMIA; BACTERIAL GENE; BACTERIAL INFECTION; BACTERIUM CULTURE; BACTERIUM ISOLATE; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; CORD BLOOD STEM CELL TRANSPLANTATION; CORTICOSTEROID THERAPY; CYTOMEGALOVIRUS INFECTION; DRUG MEGADOSE; ENTEROCOCCUS FAECALIS; FEMALE; GENE MUTATION; GENE SEQUENCE; HUMAN; KLEBSIELLA PNEUMONIAE; LIVER TOXICITY; LUNG LAVAGE; MINIMUM INHIBITORY CONCENTRATION; NEEDLE BIOPSY; NONHUMAN; NUCLEOTIDE SEQUENCE; OSTEOMYELITIS; PRIORITY JOURNAL; RECIPIENT; SEQUENCE ANALYSIS;

ACETAMIDES; ADULT; ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS; DRUG RESISTANCE, BACTERIAL; ENTEROCOCCUS FAECALIS; FEMALE; FETAL BLOOD; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; MICROBIAL SENSITIVITY TESTS; OXAZOLIDINONES; RNA, RIBOSOMAL, 23S; SEQUENCE ANALYSIS, DNA; STEM CELL TRANSPLANTATION;

BACTERIA (MICROORGANISMS); CYTOMEGALOVIRUS; ENTEROCOCCUS; ENTEROCOCCUS FAECALIS; KLEBSIELLA; KLEBSIELLA PNEUMONIAE; POSIBACTERIA; STREPTOCOCCUS;

EID: 4544268587     PISSN: 00951137     EISSN: None     Source Type: Journal    
DOI: 10.1128/JCM.42.4.1843-1845.2004     Document Type: Article

References (23)

1. Alam, A. R., G. Varma, T. Hahn, B. Segal, P. Paplham, J. Becker, M. Baer, B. Bambach, J. Silva, J. Slack, M. Wetzler, and P. L. McCarthy, Jr. 2002. Infectious complications in long-term survivors of cord blood stem cell transplantation (CBSCT); experience at Roswell Park Cancer Institute. Blood 100:629(s).
2. Auckland, C., L. Teare, F. Cooke, M. E. Kaufmann, M. Warner, G. Jones, K. Bamford, H. Ayles, and A. P. Johnson. 2002. Linezolid-resistant enterococci: report of the first isolates in the United Kingdom. J. Antimicrob. Chemother. 50:743-746.
3. Ballow, C. H., R. N. Jones, and D. J. Biedenbach. 2002. A multicenter evaluation of linezolid antimicrobial activity in North America. Diagn. Microbiol. Infect. Dis. 43:75-83.
4. Ballow, C. H., D. J. Biedenbach, F. Rossi, and R. N. Jones. 2002. Multicenter assessment of the linezolid spectrum and activity using the disk diffusion and Etest methods: report of the Zyvox (R) antimicrobial potency study in Latin America (LA-ZAPS). Braz. J. Infect. Dis. 6:100-109.
5. Barrett, J. F. 2000. Linezolid Pharmacia Corp. Curr. Opin. Investig. Drugs 1:181-187.
6. Bolmstrom, A., C. H. Ballow, A. Qwarnstrom, D. J. Biedenbach, and R. N. Jones. 2002. Multicentre assessment of linezolid antimicrobial activity and spectrum in Europe: report from the Zyvox antimicrobial potency study (ZAPS-Europe). Clin. Microbiol. Infect. 8:791-800.
7. Donskey, C. J., T. K. Chowdhry, M. T. Hecker, C. K. Hoyen, J. A. Hanrahan, A. M. Hujer, R. A. Hutton-Thomas, C. C. Whalen, R. A. Bonomo, and L. B. Rice. 2000. Effect of antibiotic therapy on the density pf vancomycin-resistant enterococci in the stool of colonized patients. N. Engl. J. Med. 343:1925-1932.
8. Eliopoulos, G. M. 2003. Quinupristin-dalfopristin and linezolid: evidence and opinion. Clin. Infect. Dis. 36:473-481.
9. Gonzales, R. D., P. C. Schreckenberger, M. B. Graham, S. Kelkar, K. DenBesten, and J. P. Quinn. 2001. Infections due to vancomycin-resistant Enterococcus faecium resistant to linezolid. Lancet 357:1179.
10. Hanna, H., J. Umphrey, J. Tarrand, M. Mendoza, and I. Raad. 2001. Management of an outbreak of vancomycin-resistant enterococci in the medical intensive care unit of a cancer center. Infect. Control Hosp. Epidemiol. 22:217-219.
11. Herrero, I. A., N. C. Issa, and R. Patel. 2002. Nosocomial spread of linezolid-resistant, vancomycin-resistant Enterococcus faecium. N. Engl. J. Med. 346:867-869.
12. Husni, R., R. Hachem, H. Hanna, and I. Raad. 2002. Risk factors for vancomycin-resistant Enterococcus (VRE) infection in colonized patients with cancer. Infect. Control Hosp. Epidemiol. 23:102-103.
13. Johnson, A. P., L. Tysall, M. V. Stockdale, N. Woodford, M. E. Kaufmann, M. Warner, D. M. Livermore, F. Asboth, and F. J. Allerberger. 2002. Emerging linezolid-resistant Enterococcus faecalis and Enterococcus faecium isolated from two Austrian patients in the same intensive care unit. Eur. J. Clin. Microbiol. Infect. Dis. 21:751-754.
14. Jones, R. N., P. Della-Latta, L. V. Lee, and D. J. Biedenbach. 2002. Linezolid-resistant Enterococcus faecium isolated from a patient without prior exposure to an oxazolidinone: report from the SENTRY Antimicrobial Surveillance Program. Diagn. Microbiol. Infect. Dis. 42:137-139.
15. Kuehnert, M. J., J. A. Jernigan, A. L. Pullen, D. Rimland, and W. R. Jarvis. 1999. Association between mucositis severity and vancomycin-resistant enterococcal bloodstream infection in hospitalized cancer patients. Infect. Control Hosp. Epidemiol. 20:660-663.
16. Marshall, S. H., C. J. Donskey, R. Hutton-Thomas, R. A. Salata, and L. B. Rice. 2002. Gene dosage and linezolid resistance in Enterococcus faecium and Enterococcus faecalis. Antimicrob. Agents Chemother. 46:3334-3336.
17. Moellering, R. C. 2003. Linezolid: the first oxazolidinone antimicrobial. Ann. Intern. Med. 138:135-142.
18. Moulin, F., S. Dumontier, P. Saulnier, E. Chachaty, C. Loubeyre, L. Brugieres, and A. Andremont. 1996. Surveillance of intestinal colonization and of infection by vancomycin-resistant enterococci in hospitalized cancer patients. Clin. Microbiol. Infect. 2:192-201.
19. NCCLS. 2002. Performance standards for antimicrobial susceptibility testing, 12th informational supplement, vol. 22, no. 1. M100-S12. NCCLS, Wayne, Pa.
20. Pitcher, D. G., N. A. Saunders, and R. J. Owen. 1989. Rapid extraction of bacterial genomic DNA with guanidium thiocyanate. Lett. Appl. Microbiol. 8:151-156.
21. Prystowsky, J., F. Siddiqui, J. Chosay, D. L. Shinabarger, J. Millichap, L. R. Peterson, and G. A. Noskin. 2001. Resistance to linezolid: characterization of mutations in rRNA and comparison of their occurrences in vancomycin-resistant enterococci. Antimicrob. Agents Chemother. 45:2154-2156.
22. Woodford, N., L. Tysall, C. Auckland, M. W. Stockdale, A. J. Lawson, R. A. Walker, and D. M. Livermore. 2002. Detection of oxazolidinone-resistant Enterococcus faecalis and Enterococcus faecium strains by real-time PCR and PCR-restriction fragment length polymorphism analysis. J. Clin. Microbiol. 40:4298-4300.
23. Zaas, A. K., X. Song, P. Tucker, and T. M. Perl. 2002. Risk factors for development of vancomycin-resistant enterococcal bloodstream infection in patients with cancer who are colonized with vancomycin-resistant enterococci. Clin. Infect. Dis. 35:1139-1146.